Bank of America Corp DE Sells 182,421 Shares of uniQure (NASDAQ:QURE)

Bank of America Corp DE reduced its stake in uniQure (NASDAQ:QURE - Free Report) by 72.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 69,064 shares of the biotechnology company's stock after selling 182,421 shares during the period. Bank of America Corp DE owned 0.14% of uniQure worth $1,220,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. Palumbo Wealth Management LLC bought a new position in shares of uniQure during the fourth quarter worth approximately $437,000. Oppenheimer & Co. Inc. acquired a new position in uniQure in the 4th quarter valued at $320,000. Raymond James Financial Inc. bought a new position in uniQure during the 4th quarter worth $1,951,000. Monaco Asset Management SAM acquired a new stake in shares of uniQure during the fourth quarter worth $2,414,000. Finally, Twin Tree Management LP acquired a new position in shares of uniQure in the fourth quarter valued at about $77,000. 78.83% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on QURE. Wall Street Zen upgraded shares of uniQure from a "sell" rating to a "hold" rating in a research note on Saturday, May 24th. Wells Fargo & Company dropped their price target on shares of uniQure from $35.00 to $30.00 and set an "equal weight" rating for the company in a research report on Friday, February 28th. Cantor Fitzgerald upgraded uniQure to a "strong-buy" rating in a research note on Monday, May 19th. Chardan Capital restated a "buy" rating and set a $38.00 price objective on shares of uniQure in a research note on Friday, May 30th. Finally, Guggenheim reaffirmed a "buy" rating and issued a $28.00 price objective on shares of uniQure in a report on Monday, May 12th. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $37.82.

uniQure Price Performance

Shares of QURE traded up $0.66 during midday trading on Friday, hitting $17.27. The company's stock had a trading volume of 1,812,893 shares, compared to its average volume of 1,919,872. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a one year low of $3.73 and a one year high of $19.18. The stock has a market capitalization of $945.98 million, a price-to-earnings ratio of -3.48 and a beta of 0.08. The company's fifty day simple moving average is $12.91 and its two-hundred day simple moving average is $13.24.

uniQure (NASDAQ:QURE - Get Free Report) last released its quarterly earnings data on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.25. The business had revenue of $1.57 million for the quarter, compared to analyst estimates of $5.93 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. As a group, equities analysts expect that uniQure will post -3.75 earnings per share for the current fiscal year.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.